常规临床实践中的免疫类型鉴定用于预测MS患者的治疗反应和不良事件
Tobias Zrzavy1,2, Kerstin Rieder1,2, Viktoria Wuketich1,2
1Department of Neurology, Medical University of Vienna, Vienna, Austria.
Frontiers in neurology
|May 1, 2024
概括
在治疗前细胞免疫类型测定可以预测多发性硬化症 (MS) 的结果. 特定的免疫细胞简介与复发风险,残疾恶化和不良事件相关,指导MS患者个性化治疗策略.
科学领域:
- 神经免疫学 神经免疫学
- 临床免疫学临床免疫学
- 生物标志物发现发现
背景情况:
- 细胞免疫造型显示出预测多发性硬化症 (pwMS) 患者的治疗反应和不良事件 (AE) 的前景.
- 免疫类型定型在指导多发性硬化症治疗决策中的实际应用性仍未得到充分研究.
研究的目的:
- 调查在疾病修饰药物 (DMD) 启动之前的常规白细胞表型测定是否可以根据治疗反应和AE对 pwMS进行分层.
- 评估在现实世界MS队列中基线免疫细胞概况和临床结果之间的关联.
主要方法:
- 追溯分析150 pwMS新开始的DMD.
- 基线免疫类型定型和随后的一年内临床评估.
- 多变量模型分析免疫子集,治疗反应和AE之间的关联.
主要成果:
- 基线CD8+ T细胞增加与更高的复发风险和EDSS恶化相关,特别是在接受抗CD20治疗的患者中.
- 较高的NK细胞比例与EDSS恶化的风险增加有关.
- 较高的T细胞百分比和较低的NKT细胞百分比在基线与AE相关.
结论:
- 免疫细胞概况与治疗反应和pwMS中的AE显著相关.
- 免疫类型定型可以作为多发性硬化症个性化治疗策略的宝贵生物标志物.
- 常规白细胞表型测定可能有助于优化MS患者的治疗决策.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Rapid Identification of Pathogens
MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...


